Navigation Links
Results of the ADVISE trial reported at TCT 2011
Date:11/11/2011

SAN FRANCISCO, CA NOVEMBER 11, 2011 Researchers conducting the ADVISE clinical trial have concluded that a new measure of stenosis severity, instantaneous wave-free ratio (iFR), yielded similar results to traditional fractional flow reserve (FFR) without the use of adenosine to induce maximum hyperemia. Trial results were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

FFR, while the leading invasive measure of stenosis severity, is only used in 6% or fewer of percutaneous coronary intervention (PCI) cases in the United States. One of the reasons for the low usage rate is the required use of the drug adenosine, which minimizes and stabilizes coronary resistance during the test, but is uncomfortable for patients, as well as being time-consuming and expensive.

In ADVISE (ADenosine Vasodilation Independent Stenosis Evaluation), 157 stenoses (131 patients) were recruited to this pilot, nonrandomized, international, multi-center study. In their investigations, researchers developed a new pressure-based index that does not require adenosine.

Wave intensity analysis identified a period during the normal heart rhythm cycle where intracoronary resistance at rest is similar in variability and magnitude (CV: 0.080.06 and 284147mmHg.s/m) to those during FFR (CV: 0.080.06 and 302315mmHg.s/m, p=NS for both).

The resting ratio of the distal-to-proximal pressure during this period, iFR, correlated closely with FFR (r=0.9, p<0.001) with excellent diagnostic efficiency (receiver operating characteristic area under curve of 93%, at FFR<0.8), specificity, sensitivity, and negative and positive predictive values of 91%, 85%, 85% and 91%, respectively.

"The results of the ADVISE trial indicate that intra-coronary resistance is naturally constant and minimized during the wave-free period. The instantaneous wave-Free Ratio (iFR) calculated over this period produces a drug-free index of stenosis severity that is comparable to FFR," said principal investigator Justin Davies, MBBS, MRCP, PhD. Dr Davies is a clinical academic and interventional cardiologist at the National Heart and Lung Institute at Imperial College London.

"The clinical implications of the trial are that significant barriers to a physiological assessment of stenoses have been removed, and the new technique can potentially improve work-flow in the cath lab, leading to a better patient experience and increased adoption," said Dr. Davies.


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2009 Financial Results
2. SXC Health Solutions to Host Fiscal 2009 Fourth Quarter and Year End Results Conference Call
3. Team Health Holdings, Inc., Announces Fourth Quarter and Fiscal 2009 Financial Results
4. First blinded study of venous insufficiency prevalence in MS shows promising results
5. NEJM Publishes Trial Results Demonstrating Bard FLAIR Endovascular Stent Graft Is Superior To Balloon Angioplasty For Failing Dialysis Grafts
6. BioMed Realty Trust Reports Fourth Quarter and Full-Year 2009 Financial Results
7. Kaiser Foundation Health Plan and Hospitals Report Fourth Quarter and Fiscal Year 2009 Financial Results
8. United American Healthcare Corporation Announces Fiscal 2010 Second Quarter Results
9. Fitness Trend Towards Online Personal Training Gets Real-World Weight Loss Results on FitOrbit.com
10. Protein Sciences Corporation Announces Profitable and Cash Flow Positive Results for 2009 and Management Realignment
11. WebMD Announces Fourth Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... ... The Aging in Motion Coalition (AIM) has announced the Centers ... it recognition for separate reporting and data collection. The code, M62.84, will be available ... as a combination of low muscle mass and weakness in older adults that causes ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... by a health insurance co-operative bankruptcy to receive their prescription medications through ... over 1,500 FDA-approved prescription medications from over 180 American pharmaceutical companies for ...
(Date:4/28/2016)... ... April 28, 2016 , ... Today Nimblify, Inc. ... Calendar Exchange , is officially open to all sponsors in the industry. The ... to download into their clinical trial management system (CTMS), which is the site’s ...
(Date:4/28/2016)... ... April 28, 2016 , ... On ... Officer at the Steadman Philippon Research Institute in Vail, Colorado, attended the ... awareness about the debilitating and costly musculoskeletal disorders that are affecting millions of ...
(Date:4/28/2016)... Valley, California (PRWEB) , ... ... ... Inc. (AGNITY) a leading global provider of intelligent business communication applications and ... and go-live of its Number Portability solution at Bestel’s Communications Network. ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 2016 Dr. ... und Stephen Schmidt werden ... ArisGlobal®, ein führender Anbieter cloudbasierter Softwarelösungen für ... dass neue Führungskräfte zum Team Sicherheit und ... vielfältige Erfahrungen mitbringen.  Dies wird die Geschäftseinheit ...
(Date:4/28/2016)... -- Dr. Vivek Ahuja , ... Ste phen Schmidt Join ... cloud-based software solutions for life sciences, today announced key new leaders ... of insight to a growing business.  This will bolster the company,s ... Phillips joined ArisGlobal in the position of Vice President - ...
(Date:4/28/2016)... Florida , April 28, 2016 ... the development of innovative peptide and gene-based immunotherapeutics and vaccines ... it will be presenting at the 3rd Annual Growth ... - 5 th , 2016 at Caesars Palace in Las Vegas, ... 8.00 am on Wednesday, May 4 th by Dr. ...
Breaking Medicine Technology: